

Natural Support For Stomach Health

References

1. Lochhead P, El-Omar EM. Helicobacter pylori infection and gastric cancer. *Best Pract Res Clin Gastroenterol*. 2007;21(2):281-97.
2. Wilson KT, Crabtree JE. Immunology of Helicobacter pylori: insights into the failure of the immune response and perspectives on vaccine studies. *Gastroenterology*. 2007 Jul;133(1):288-308.
3. Available at: http://www.nobelprize.org/nobel_prizes/medicine/laureates/2005/press.html. Accessed March 27, 2015.
4. Lesbros-Pantoflickova D, Corthesy-Theulaz I, Blum AL. Helicobacter pylori and probiotics. *J Nutr*. 2007 Mar;137(3 Suppl 2):812S-8S.
5. Available at: <http://gi.org/guideline/management-of-helicobacter-pylori-infection/>. Accessed March 27, 2015.
6. Davidson G, Kritas S, Butler R. Stressed mucosa. *Nestle Nutr Workshop Ser Pediatr Program*. 2007;59:133-42.
7. Boeckxstaens GE. Neuroimmune interaction in the gut: from bench to bedside. *Verh K Acad Geneeskd Belg*. 2006;68(5-6):329-55.
8. Iezzi A, Ferri C, Mezzetti A, Cipollone F. COX-2: friend or foe? *Curr Pharm Des*. 2007;13(16):1715-21.
9. Fox JG, Wang TC. Inflammation, atrophy, and gastric cancer. *J Clin Invest*. 2007 Jan;117(1):60-9.
10. Dalal RS, Moss SF. At the bedside: Helicobacter pylori, dysregulated host responses, DNA damage, and gastric cancer. *J Leukoc Biol*. 2014 Aug;96(2):213-24.
11. Hardbower DM, Peek RM Jr, Wilson KT. At the Bench: Helicobacter pylori, dysregulated host responses, DNA damage, and gastric cancer. *J Leukoc Biol*. 2014 Aug;96(2):201-12.
12. D'Elia MM, Montecucco C, de BM. VacA and HP-NAP, Ying and Yang of Helicobacter pylori-associated gastric inflammation. *Clin Chim Acta*. 2007 May;381(1):32-8.
13. Lai LH, Sung JJ. Helicobacter pylori and benign upper digestive disease. *Best Pract Res Clin Gastroenterol*. 2007;21(2):261-79.
14. Müller A, Oertli M, Arnold IC. H. pylori exploits and manipulates innate and adaptive immune cell signaling pathways to establish persistent infection. *Cell Commun Signal*. 2011 Nov 1;9(1):25.
15. Robinson K, Argent RH, Atherton JC. The inflammatory and immune response to Helicobacter pylori infection. *Best Pract Res Clin Gastroenterol*. 2007;21(2):237-59.
16. Gotz JM, van Kan CI, Verspaget HW, et al. Gastric mucosal superoxide dismutases in Helicobacter pylori infection. *Gut*. 1996 Apr;38(4):502-6.
17. Gotz JM, Thio JL, Verspaget HW, et al. Treatment of Helicobacter pylori infection favourably affects gastric mucosal superoxide dismutases. *Gut*. 1997 May;40(5):591-6.
18. Lin YT, Kwon YI, Labbe RG, Shetty K. Inhibition of Helicobacter pylori and associated urease by oregano and cranberry phytochemical synergies. *Appl Environ Microbiol*. 2005 Dec;71(12): 8558-64.
19. O'Mahony R, Al-Khtheeri H, Weerasekera D, et al. Bactericidal and anti-adhesive properties of culinary and medicinal plants against Helicobacter pylori. *World J Gastroenterol*. 2005 Dec 21;11(47):7499-507.

20. Varas Lorenzo MJ, Lopez MA, Gordillo BJ, Mundet SJ. Comparative study of 3 drugs (aceglutamide aluminum, zinc acexamate, and magaldrate) in the long-term maintenance treatment (1 year) of peptic ulcer. *Rev Esp Enferm Dig.* 1991 Aug;80(2):91-4.
21. Rodriguez de la SA, az-Rubio M. Multicenter clinical trial of zinc acexamate in the prevention of nonsteroidal antiinflammatory drug induced gastroenteropathy. *J Rheumatol.* 1994 May;21(5):927-33.
22. Barrera JL, Verastegui E, Meneses A, et al. Combination immunotherapy of squamous cell carcinoma of the head and neck: a phase 2 trial. *Arch Otolaryngol Head Neck Surg.* 2000 Mar;126(3):345-51.
23. Matsukura T, Tanaka H. Applicability of zinc complex of L-carnosine for medical use. *Biochemistry (Mosc).* 2000 Jul;65(7):817-23.
24. Sakae K, Yanagisawa H. Oral treatment of pressure ulcers with polaprezinc (zinc L-carnosine complex): 8-week open-label trial. *Biol Trace Elem Res.* 2014 Jun;158(3):280-8.
25. Furuta S, Toyama S, Miwa M, et al. Residence time of polaprezinc (zinc L-carnosine complex) in the rat stomach and adhesiveness to ulcerous sites. *Jpn J Pharmacol.* 1995 Apr;67(4):271-8.
26. Hiraishi H, Sasai T, Oinuma T, et al. Polaprezinc protects gastric mucosal cells from noxious agents through antioxidant properties in vitro. *Aliment Pharmacol Ther.* 1999 Feb;13(2):261-9.
27. Nishiwaki H, Kato S, Sugamoto S, et al. Ulcerogenic and healing impairing actions of monochloramine in rat stomachs: effects of zinc L-carnosine, polaprezinc. *J Physiol Pharmacol.* 1999 Jun;50(2):183-95.
28. Watanabe S, Wang XE, Hirose M, et al. Insulin-like growth factor I plays a role in gastric wound healing: evidence using a zinc derivative, polaprezinc, and an in vitro rabbit wound repair model. *Aliment Pharmacol Ther.* 1998 Nov;12(11):1131-8.
29. Kato S, Tanaka A, Ogawa Y, et al. Effect of polaprezinc on impaired healing of chronic gastric ulcers in adjuvant-induced arthritic rats—role of insulin-like growth factors (IGF)-1. *Med Sci Monit.* 2001 Jan;7(1):20-5.
30. Suzuki H, Mori M, Seto K, et al. Polaprezinc, a gastroprotective agent: attenuation of monochloramine-evoked gastric DNA fragmentation. *J Gastroenterol.* 1999;34 Suppl 1143-6.
31. Cho CH, Luk CT, Ogle CW. The membrane-stabilizing action of zinc carnosine (Z-103) in stress-induced gastric ulceration in rats. *Life Sci.* 1991;49(23):L189-94.
32. Shimada T, Watanabe N, Ohtsuka Y, et al. Polaprezinc down-regulates proinflammatory cytokine-induced nuclear factor-kappaB activation and interleukin-8 expression in gastric epithelial cells. *J Pharmacol Exp Ther.* 1999 Oct;291(1):345-52.
33. Suzuki H, Mori M, Seto K, et al. Polaprezinc attenuates the Helicobacter pylori-induced gastric mucosal leucocyte activation in Mongolian gerbils—a study using intravital videomicroscopy. *Aliment Pharmacol Ther.* 2001 May;15(5):715-25.
34. Kashimura H, Suzuki K, Hassan M, et al. Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. *Aliment Pharmacol Ther.* 1999 Apr;13(4):483-7.
35. Cho CH, Ogle CW. The pharmacological differences and similarities between stress- and ethanol-induced gastric mucosal damage. *Life Sci.* 1992;51(24):1833-42.
36. Arakawa T, Satoh H, Nakamura A, et al. Effects of zinc L-carnosine on gastric mucosal and cell damage caused by ethanol in rats. Correlation with endogenous prostaglandin E2. *Dig Dis Sci.* 1990 May;35(5):559-66.
37. Cho CH, Hui WM, Chen BW, Luk CT, Lam SK. The cytoprotective effect of zinc L-carnosine on ethanol-induced gastric gland damage in rabbits. *J Pharm Pharmacol.* 1992 Apr;44(4):364-5.

38. Ito M, Tanaka T, Suzuki Y. Effect of N-(3-aminopropionyl)-L-histidinato zinc (Z-103) on healing and hydrocortisone-induced relapse of acetic acid ulcers in rats with limited food-intake-time. *Jpn J Pharmacol*. 1990 Apr;52(4):513-21.
39. Seiki M, Ueki S, Tanaka Y, et al. Studies on anti-ulcer effects of a new compound, zinc L-carnosine (Z-103). *Nippon Yakurigaku Zasshi*. 1990 May;95(5):257-69.
40. Yoshikawa T, Naito Y, Tanigawa T, et al. Effect of zinc-carnosine chelate compound (Z-103), a novel antioxidant, on acute gastric mucosal injury induced by ischemia-reperfusion in rats. *Free Radic Res Commun*. 1991;14(4):289-96.
41. Mahmood A, FitzGerald AJ, Marchbank T, et al. Zinc carnosine, a health food supplement that stabilises small bowel integrity and stimulates gut repair processes. *Gut*. 2007 Feb;56(2):168-75.
42. Aburaya M, Tanaka K, Hoshino T, et al. Heme oxygenase-1 protects gastric mucosal cells against non-steroidal anti-inflammatory drugs. *J Biol Chem*. 2006 Nov 3;281(44):33422-32.
43. Almolki A, Guenegou A, Golda S, et al. Heme oxygenase-1 prevents airway mucus hypersecretion induced by cigarette smoke in rodents and humans. *Am J Pathol*. 2008 Oct;173(4):981-92.
44. Ueda K, Ueyama T, Oka M, Ito T, Tsuruo Y, Ichinose M. Polaprezinc (Zinc L-carnosine) is a potent inducer of anti-oxidative stress enzyme, heme oxygenase (HO)-1 - a new mechanism of gastric mucosal protection. *J Pharmacol Sci*. 2009 Jul;110(3):285-94.
45. Choi HS, Lim JY, Chun HJ, et al. The effect of polaprezinc on gastric mucosal protection in rats with ethanol-induced gastric mucosal damage: comparison study with rebamipide. *Life Sci*. 2013 Jul 30;93(2-3):69-77.
46. Lin YT, Kwon YI, Labbe RG, Shetty K. Inhibition of Helicobacter pylori and associated urease by oregano and cranberry phytochemical synergies. *Appl Environ Microbiol*. 2005 Dec;71(12): 8558-64.
47. Vatter DA, Ghaedian R, Shetty K. Enhancing health benefits of berries through phenolic antioxidant enrichment: focus on cranberry. *Asia Pac J Clin Nutr*. 2005;14(2):120-30.
48. Burger O, Weiss E, Sharon N, et al. Inhibition of Helicobacter pylori adhesion to human gastric mucus by a high-molecular-weight constituent of cranberry juice. *Crit Rev Food Sci Nutr*. 2002;42(3 Suppl):279-84.
49. Zhang L, Ma J, Pan K, et al. Efficacy of cranberry juice on Helicobacter pylori infection: a double-blind, randomized placebo-controlled trial. *Helicobacter*. 2005 Apr;10(2):139-45.
50. Shmueli H, Yahav J, Samra Z, et al. Effect of cranberry juice on eradication of Helicobacter pylori in patients treated with antibiotics and a proton pump inhibitor. *Mol Nutr Food Res*. 2007 Jun;51(6):746-51.
51. Gotteland M, Brunser O, Cruchet S. Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? *Aliment Pharmacol Ther*. 2006 Apr 15;23(8):1077-86.
52. Côté J, Caillet S, Doyon G, Sylvain JF, Lacroix M. Bioactive compounds in cranberries and their biological properties. *Crit Rev Food Sci Nutr*. 2010 Aug;50(7):666-79.
53. Fukai T, Marumo A, Kaitou K, et al. Anti-Helicobacter pylori flavonoids from licorice extract. *Life Sci*. 2002 Aug 9;71(12):1449-63.
54. Krausse R, Bielenberg J, Blaschek W, Ullmann U. In vitro anti-Helicobacter pylori activity of Extractum liquiritiae, glycyrrhizin and its metabolites. *J Antimicrob Chemother*. 2004 Jul;54(1):243-6.
55. Emer J, Waldorf H, Berson D. Botanicals and anti-inflammatories: natural ingredients for rosacea. *Semin Cutan Med Surg*. 2011 Sep;30(3):148-55.
56. Aly AM, Al-Alousi L, Salem HA. Licorice: a possible anti-inflammatory and anti-ulcer drug. *AAPS PharmSciTech*. 2005;6(1): E74-E82.

57. Rees WD, Rhodes J, Wright JE, Stamford LF, Bennett A. Effect of deglycyrrhizinated liquorice on gastric mucosal damage by aspirin. *Scand J Gastroenterol*. 1979;14(5):605-7.
58. Larkworthy W, Holgate PF. Deglycyrrhizinated liquorice in the treatment of chronic duodenal ulcer. A retrospective endoscopic survey of 32 patients. *Practitioner*. 1975 Dec;215(1290):787-92.
59. Morgan AG, McAdam WA, Pacsoo C, Darnborough A. Comparison between cimetidine and Caved-S in the treatment of gastric ulceration, and subsequent maintenance therapy. *Gut*. 1982 Jun;23(6):545-51.
60. Morgan AG, Pacsoo C, McAdam WA. Maintenance therapy: a two year comparison between Caved-S and cimetidine treatment in the prevention of symptomatic gastric ulcer recurrence. *Gut*. 1985 Jun;26(6):599-602.
61. Momeni A, Rahimian G, Kiasi A, Amiri M, Kheiri S. Effect of licorice versus bismuth on eradication of *Helicobacter pylori* in patients with peptic ulcer disease. *Pharmacognosy Res*. 2014 Oct;6(4):341-4.
62. [No authors listed] *Picrorhiza kurroa*. Monograph. *Altern Med Rev*. 2001 Jun;6(3):319-21.
63. Chander R, Kapoor NK, Dhawan BN. Effect of picroliv on glutathione metabolism in liver and brain of *Mastomys natalensis* infected with *Plasmodium berghei*. *Indian J Exp Biol*. 1992 Aug;30(8):711-4.
64. Chander R, Singh K, Visen PK, Kapoor NK, Dhawan BN. Picroliv prevents oxidation in serum lipoprotein lipids of *Mastomys coucha* infected with *Plasmodium berghei*. *Indian J Exp Biol*. 1998 Apr;36(4):371-4.
65. Sun M, Fan HW, Ma HY, Zhu Q. Protective effect of total glucosides of *Picrorhiza scrophulariiflora* against oxidative stress in glomerular mesangial cells induced by high glucose. *Yao Xue Xue Bao*. 2007 Apr;42(4):381-5.
66. Vaidya AB, Antarkar DS, Doshi JC, et al. *Picrorhiza kurroa* (Kutaki) Royle ex Benth as a hepatoprotective agent—experimental & clinical studies. *J Postgrad Med*. 1996 Oct;42(4):105-8.
67. Gupta A, Khajuria A, Singh J, et al. Immunomodulatory activity of biopolymeric fraction RLJ-NE-205 from *Picrorhiza kurroa*. *Int Immunopharmacol*. 2006 Oct;6(10):1543-9.
68. Puri A, Saxena RP, Guru PY, et al. Immunostimulant Activity of Picroliv, the Iridoid Glycoside Fraction of *Picrorhiza kurroa*, and its Protective Action against *Leishmania donovani* Infection in Hamsters1. *Planta Med*. 1992 Dec;58(6):528-32.
69. Sharma ML, Rao CS, Duda PL. Immunostimulatory activity of *Picrorhiza kurroa* leaf extract. *J Ethnopharmacol*. 1994 Feb;41(3):185-92.
70. Smit HF, Kroes BH, van den Berg AJ, et al. Immunomodulatory and anti-inflammatory activity of *Picrorhiza scrophulariiflora*. *J Ethnopharmacol*. 2000 Nov;73(1-2):101-9.
71. Barbieri SS, Cavalca V, Eligini S, et al. Apocynin prevents cyclooxygenase 2 expression in human monocytes through NADPH oxidase and glutathione redox-dependent mechanisms. *Free Radic Biol Med*. 2004 Jul 15;37(2):156-65.
72. Thomas M, Sheran J, Smith N, Fonseca S, Lee AJ. AKL1, a botanical mixture for the treatment of asthma: a randomised, double-blind, placebo-controlled, cross-over study. *BMC Pulm Med*. 2007;74.
73. Zhang Y, DeWitt DL, Murugesan S, Nair MG. Novel lipid-peroxidation- and cyclooxygenase-inhibitory tannins from *Picrorhiza kurroa* seeds. *Chem Biodivers*. 2004 Mar;1(3):426-41.
74. Zhang Y, DeWitt DL, Murugesan S, Nair MG. Cyclooxygenase-2 enzyme inhibitory triterpenoids from *Picrorhiza kurroa* seeds. *Life Sci*. 2005 Nov 4;77(25):3222-30.
75. Ray A, Chaudhuri SR, Majumdar B, Bandyopadhyay SK. Antioxidant activity of ethanol extract of rhizome of *Picrorhiza kurroa* on indomethacin induced gastric ulcer during healing. *Indian J Clin Biochem*. 2002;17(2):44-51.

76. Banerjee D, Maity B, Nag SK, Bandyopadhyay SK, Chattopadhyay S. Healing potential of *Picrorhiza kurroa* (Scrophulariaceae) rhizomes against indomethacin-induced gastric ulceration: a mechanistic exploration. *BMC Complement Altern Med*. 2008 Jan 31;8:3.
77. Kassem M, Eriksen EF, Melsen F, Mosekilde L. Antacid-induced osteomalacia: a case report with a histomorphometric analysis. *J Intern Med*. 1991 Mar;229(3):275-9.
78. Krewski D, Yokel RA, Nieboer E, et al. Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide. *J Toxicol Environ Health B Crit Rev*. 2007;10 Suppl 1:1-269.
79. Ruscin JM, Page RL 2nd, Valuck RJ. Vitamin B(12) deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor. *Ann Pharmacother*. 2002 May;36(5):812-6.
80. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. *J Clin Epidemiol*. 2004 Apr;57(4):422-8.
81. Oh S. Proton pump inhibitors--uncommon adverse effects. *Aust Fam Physician*. 2011 Sep;40(9):705-8.
82. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. *Am J Gastroenterol*. 2009 Mar;104 Suppl 2:S27-32.
83. Roulet L, Vernaz N, Giostra E, Gasche Y, Desmeules J. Adverse effects of proton pump inhibitors: Should we worry about long-term exposure? *Rev Med Interne*. 2012 Aug;33(8):439-45.